Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Myotrophin

Executive Summary

FDA Peripheral & CNS Drugs Advisory Committee will revisit Chiron/Cephalon's NDA for Myotrophin (mecasermin) for treatment of amyotrophic lateral sclerosis April 9. The committee has considered the drug twice before, once at the Treatment IND stage and once at the NDA stage, and both times said that another study would be required to support approval. Cephalon has refused to invest more in the project prior to approval. The meeting will take place at the Bethesda, Md. Holiday Inn beginning at 8:30 a.m...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel